Payment overview · 2025
General Payments
$376.86
20 reported records · 12 companies
Healthcare provider profile · identity verified
Iris Kalin Clark, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STATESBORO, GA · NPI 1174887004
Verified facts
What the public records show
CMS Open Payments records show Iris Kalin Clark, M.D. received $376.86 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.31 | 19.4% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $49.29 | 13.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.02 | 10.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.71 | 9.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.12 | 9.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.27 | 7.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.16 | 6.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.15 | 6.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.60 | 4.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.45 | 4.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.18 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.60 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $376.86 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $73.31 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $49.29 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
227 | 26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 623 | 138 |
| Oxycodone Hcl | Oxycodone Hcl | 556 | 63 |
| Montelukast Sodium | Montelukast Sodium | 552 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 527 | 64 |
| Gabapentin | Gabapentin | 491 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 486 | 102 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 408 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 391 | 67 |
| Losartan Potassium | Losartan Potassium | 356 | 66 |
| Omeprazole | Omeprazole | 312 | 66 |
| Lisinopril | Lisinopril | 299 | 70 |
| Tizanidine Hcl | Tizanidine Hcl | 288 | 58 |
| Prednisone | Prednisone | 282 | 158 |
| Potassium Chloride | Potassium Chloride | 275 | 59 |
| Furosemide | Furosemide | 259 | 63 |
| Carvedilol | Carvedilol | 255 | 50 |
| Metformin Hcl | Metformin Hcl | 255 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 251 | 60 |
| Pregabalin | Pregabalin | 250 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 48 |
| Meloxicam | Meloxicam | 237 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 231 | 55 |
| Eliquis | Apixaban | 227 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 46 |
| Sertraline Hcl | Sertraline Hcl | 203 | 34 |
| Januvia | Sitagliptin Phosphate | 202 | 27 |
| Trazodone Hcl | Trazodone Hcl | 185 | 37 |
| Mirtazapine | Mirtazapine | 174 | 35 |
| Donepezil Hcl | Donepezil Hcl | 169 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 161 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 156 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 27 |
| Glipizide | Glipizide | 140 | 25 |
| Memantine Hcl | Memantine Hcl | 132 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 128 | 22 |
| Lorazepam | Lorazepam | 126 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 25 |
| Buspirone Hcl | Buspirone Hcl | 122 | 17 |
| Famotidine | Famotidine | 120 | 25 |
| Alprazolam | Alprazolam | 117 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 21 |
| Tramadol Hcl | Tramadol Hcl | 114 | 37 |
| Finasteride | Finasteride | 108 | 17 |
| Ondansetron Odt | Ondansetron | 106 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 16 |
| Xarelto | Rivaroxaban | 98 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 15 |
| Divalproex Sodium | Divalproex Sodium | 96 | 11 |
| Azithromycin | Azithromycin | 91 | 71 |
| Allopurinol | Allopurinol | 90 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 18 |
| Cephalexin | Cephalexin | 86 | 45 |
| Ibuprofen | Ibuprofen | 80 | 20 |
| Promethazine Hcl | Promethazine Hcl | 78 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 23 |
| Farxiga | Dapagliflozin Propanediol | 77 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 51 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 39 |
| Jardiance | Empagliflozin | 73 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 18 |
| Simvastatin | Simvastatin | 70 | 17 |
| Tradjenta | Linagliptin | 70 | 12 |
| Bupropion Xl | Bupropion Hcl | 68 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 16 |
| Clonazepam | Clonazepam | 66 | 22 |
| Fentanyl | Fentanyl | 65 | 14 |
| Methocarbamol | Methocarbamol | 64 | 13 |
| Temazepam | Temazepam | 64 | suppressed |
| Aripiprazole | Aripiprazole | 63 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 32 |
| Topiramate | Topiramate | 58 | suppressed |
| Celecoxib | Celecoxib | 57 | suppressed |
| Fluconazole | Fluconazole | 57 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | suppressed |
| Baclofen | Baclofen | 56 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | suppressed |
| Spironolactone | Spironolactone | 56 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 13 |
| Linzess | Linaclotide | 54 | 17 |
| Ozempic | Semaglutide | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 15 |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | suppressed |
| Estradiol | Estradiol | 49 | suppressed |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 17 |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | 11 |
| Glipizide Er | Glipizide | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Risperidone | Risperidone | 48 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 47 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Atenolol | Atenolol | 40 | 11 |
| Sucralfate | Sucralfate | 38 | 12 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 21 |
| Insulin Aspart Flexpen | Insulin Aspart | 35 | suppressed |
| Lidocaine | Lidocaine | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 15 |
| Levofloxacin | Levofloxacin | 33 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 23 |
| Latanoprost | Latanoprost | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Copaxone | Glatiramer Acetate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 13 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 24 | 23 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 12 |
| Enulose | Lactulose | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $376.86 · 20 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, GARDASIL 9, General - Pain Management, Kerendia, PREVNAR 20, The Cologuard Plus Collection Kit, VERQUVO, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error